Sign up to save your podcasts
Or
Share Kymera Therapeutics' Founder & CEO Nello Mainolfi discusses the safety, degradation, and biomarker profile he sees in the company's STAT6 healthy volunteer data
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Kymera Therapeutics' Founder & CEO Nello Mainolfi discusses the safety, degradation, and biomarker profile he sees in the company's STAT6 healthy volunteer data
He describes the data, which was released on Monday, and highlights the future of the program - including how we will see more data in atopic dermatitis patients by the end of the year. Plus, discussing a new target Kymera recently announced for other immuno-inflammatory diseases, IRF5.
View all episodes
By BiotechTV
4.3
66 ratings
He describes the data, which was released on Monday, and highlights the future of the program - including how we will see more data in atopic dermatitis patients by the end of the year. Plus, discussing a new target Kymera recently announced for other immuno-inflammatory diseases, IRF5.
More shows like BiotechTV - News
View all
Motley Fool Money
3,223 Listeners
Odd Lots
1,902 Listeners
The Long Run with Luke Timmerman
123 Listeners
The Readout Loud
324 Listeners
Biotech 2050 Podcast
61 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
9,960 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Business Breakdowns
353 Listeners
Biotech Hangout
19 Listeners
Bloomberg Tech
60 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
514 Listeners
Uncapped with Jack Altman
41 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
2 Listeners
BioVenture VoiCes with Chris Garabedian
6 Listeners
Cheeky Pint
46 Listeners